Navigate Disruptions to Care that Affect Health, Budgets and Operations

The healthcare landscape is growing more complex seemingly by the day – and that was leading the industry down a dark path toward worried patients and overwhelmed physicians when it comes to the intricate web of payments, budgeting and operations.

That’s why Co-founder and President Ryan Coplon formed HealthWallet.

The “health concierge” service offers a single app that includes plan info, prescription market information, telehealth, and much more, offering users “a suite of best-in-class digital healthcare technology features to bring convenience and transparency to the already complex and confusing healthcare system.”

On the premiere episode of Digital Disruption, Coplon joined host Daniel Litwin to explore how HealthWallet came to be, as well as the challenges he’s seen in the healthcare landscape that he hopes the company can answer and his forecast for future episodes of the show, which will continue to dive into difficult and challenging topics on the path toward better solutions.

“HealthWallet, at its core, is a benefits-aggregation platform,” Coplon said. “It’s a mobile-native technology system that aggregates a suite of benefits together and consolidates them.

“We’ve taken a pretty complex digital healthcare ecosystem and created an intentionally easy to understand and utilize mobile platform that not only will aggregate benefits together into an environment that’s easy to access for members and their families, but uses some proactive automation and technology to engage them in a timely way.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Recent Episodes

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…